Legend Biotech
LEGN
61 hedge funds and large institutions have $723M invested in Legend Biotech in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 9 closing their positions.
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
22% more funds holding
Funds holding: 50 → 61 (+11)
0.35% more ownership
Funds ownership: 9.3% → 9.65% (+0.35%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
4% less capital invested
Capital invested by funds: $751M → $723M (-$27.8M)
Top Buyers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$22.5M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$12.4M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$12M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.85M |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
+$6.87M |
Top Sellers
LEGN Hedge Fund Activity: Q4 2020 in Review
61 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q4 2020, worth a combined $723M — down 3.7% from $751M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new LEGN positions and 9 closed out — a net gain of 11 holders — while 16 added to existing stakes and 16 trimmed.
The largest buyer was Federated Hermes, adding an estimated $22.5M. The largest seller was Vivo Capital, cutting an estimated $16.6M.
- 61 institutional investors held Legend Biotech (LEGN) as of Q4 2020, up from 50 in Q3 2020.
- Funds reported $723M of Legend Biotech stock for Q4 2020, down 3.7% quarter-over-quarter.
- 20 funds opened new Legend Biotech positions in Q4 2020 and 9 closed out, a net change of +11 holders.
- The largest Legend Biotech buyer in Q4 2020 was Federated Hermes, an estimated $22.5M added.
- The largest Legend Biotech seller in Q4 2020 was Vivo Capital, an estimated $16.6M sold.
Based on aggregated 13F filings for Q4 2020.